Various aspects of the present disclosure relate generally to ocular tissue treatment. More specifically, the present disclosure relates to instruments and related methods for reducing intraocular eye pressure.
Glaucoma is a disease resulting from an increase in intraocular eye pressure (TOP). IOP may increase when natural drainage of the eye (e.g., drainage of the humus of the eye) is prevented, reduced, or otherwise blocked. Cavities in front of (e.g., on top of) the lens of the eye are filled with a viscous fluid called aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste (e.g., foreign object debris) from these tissues. In a healthy eye, a stream of aqueous humor drains out of the anterior chamber of the eye through the trabecular meshwork and into Schlemm's canal as new aqueous humor is secreted by the epithelial cells of the ciliary body. The drained aqueous humor enters the venous blood stream from Schlemm's canal and is carried along with the venous blood leaving the eye. When the natural drainage mechanisms of the eye (e.g., Schlemm's canal and/or the trabecular meshwork) stop functioning properly, the IOP begins to increase.
Prior treatments to reduce TOP may include application of eye drops and other medications. Application of such medications may be required multiple times a day, and may interfere with a patient's quality of life. Additionally, laser treatments and other surgical applications may be used to reduce TOP, however, such treatments may be invasive and often provide only temporary reduction of TOP.
The systems, devices, and methods of the current disclosure may rectify some of the deficiencies described above or address other aspects of the prior art.
At least one aspect is directed to a medical device. The medical device includes a microcannula having a proximal end, a distal end, a cavity, and a central longitudinal axis. The medical device includes a handled, coupled to the proximal end of the microcannula. The microcannula includes multiple orifices, extending circumferentially about the microcannula distal end. Each orifice defines a channel extending transverse to the central longitudinal axis, and one or more grooves about a circumference of the microcannula.
In some implementations, an outer diameter of the microcannula varies along a length of the microcannula.
In some implementations, an inner diameter of the microcannula varies along a length of the microcannula.
In some implementations, a first orifice among the orifices is spaced 180 degrees apart from a second orifice among the multiple of orifices.
In some implementations, each of the one or more grooves have a depth between 15 μm and 35 μm.
In some implementations, each of the one or more grooves are formed proximal to the orifices.
In some implementations, each of the one or more grooves is spaced apart from another groove by a distance between 40 μm and 60 μm.
At least one aspect is directed to a medical device that includes a first cannula having a distal end, and a cavity, the first cannula having a central longitudinal axis, and protrusions. The protrusions of the first cannula extend circumferentially at the distal end of the first cannula and are located in the cavity of the first cannula. The medical device includes a second cannula having a distal end, and a cavity. The second cannula is moveably housed within the first cannula and has a central longitudinal axis, protrusions, and a plurality of orifices extending circumferentially about the distal end of the second cannula. The protrusions of the second cannula extend circumferentially at the distal end of the second cannula and are located on an outer circumferential surface of the second cannula. A first orifice among the plurality of orifices is positioned parallel to a second orifice among the plurality of orifices.
In some implementations, the second cannula includes one or more grooves about a circumference of the second cannula.
In some implementations, the one or grooves of the second cannula are located at the distal end of the second cannula.
In some implementations, the one or more grooves are equidistantly spaced apart.
In some implementations, each of the protrusions of the first cannula are equidistantly spaced apart.
In some implementations, the protrusions of the second cannula are proximal to a user than the protrusions of the first cannula when the distal end of the second cannula is within the first cannula.
In some implementations, the protrusions of the second cannula are distal to a user than the protrusions of the second cannula when at least a portion of the distal end of the second cannula is moved outside of the distal end of the first cannula.
At least one aspect is directed to a method of delivering fluid into the eye. The method includes inserting a microcannula through an incision in an anterior chamber of an eye. The microcannula including a proximal end, a distal end, and a cavity, the microcannula having a central longitudinal axis. Advancing the microcannula distal end through a trabecular meshwork of an eye and into Schlemm's canal of an eye. Delivering fluid through a plurality of orifices each of which being positioned within Schlemm's canal, each orifice defining a channel extending circumferentially about the microcannula distal end.
In some implementations, the channel of the orifice of the plurality of orifices extends transverse to the central longitudinal axis.
In some implementations, the microcannula includes one or more grooves about a circumference of the microcannula at the distal end of the microcannula.
In some implementations, the microcannula includes one or more protrusions extending circumferentially at the distal end of the microcannula and located on an outer circumferential surface of the microcannula. The microcannula is movably housed within a second cannula, the second cannula having one or more protrusions extending circumferentially at a distal end of the second cannula and located a cavity of the second cannula.
In some implementations, the step of advancing the microcannula distal end further includes applying a force to the microcannula to move the one or more protrusions of the microcannula distal to a user and past the one or more protrusions of the second cannula.
At least one aspect is directed to a medical device. The medical device includes a microcannula having a proximal end, a distal end, a cavity, and a central longitudinal axis. The medical device includes a handled, coupled to the proximal end of the microcannula. The microcannula includes multiple orifices, extending circumferentially about the microcannula distal end. Each orifice defines a channel extending transverse to the central longitudinal axis, and one or more protrusions about a circumference of the microcannula.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate exemplary aspects of the present disclosure and together with the description, serve to explain the principles of the disclosure.
The following detailed description is exemplary and explanatory only and is not restrictive of the features, as claimed. As used herein, the terms “comprises,” “comprising,” or other variations thereof, are intended to cover a non-exclusive inclusion such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements, but may include other elements not expressly listed or inherent to such a process, method, article, or apparatus. Additionally, the term “exemplary” is used herein in the sense of “example,” rather than “ideal.” As used herein, the terms “about,” “substantially,” and “approximately,” indicate a range of values within +/−5% of a stated value. The term “distal” refers to a portion farthest away from a user when introducing a device into a subject. By contrast, the term “proximal” refers to a portion closest to the user when placing the device into the subject.
As shown in
A radially outer circumferential surface of connector body 26 may be knurled, ribbed, or otherwise textured to enhance a medical professional's grasp of handle 12. In some arrangements, at least one of connector 16 and distal end 20 includes a fluid luer port (not shown). The fluid luer port may extend radially away from connector 16 and/or distal end 20, and may be configured for connection to interchangeable external reservoirs. In such a manner, a reservoir 28 (
As shown in
In some implementations, microcannula 14 may have an outer diameter with varying sizes along the length of the microcannula 14. For example, as shown in
Microcannula 14 may have an inner diameter with varying sizes along the length of the microcannula 14. For example, an inner diameter near the proximal end of microcannula 14 may be between about 300 μm and 500 μm, such as 400 μm, and an inner diameter near the distal end of the microcannula 14 may be of a different size than the inner diameter near the proximal end. In some implementations, the inner diameter of microcannula 14 may be tapered down from the inner diameter near the proximal end to the inner diameter near the distal end starting from a certain distance away from the terminal end of microcannula 14. In some implementations, the inner diameter of microcannula 14 may be tapered down starting from the location of a circumferential groove on the microcannula 14, for example, a circumferential groove closest to the proximal end of microcannula 14, such as circumferential groove 99a in
Microcannula 14 may include one or more grooves about the circumference of microcannula 14 (referred to herein as “circumferential grooves”), such as circumferential grooves 99a, 99b, 99c. In some implementations, as shown in
In some implementations, microcannula 14 may include one or more protrusions about the circumference of microcannula 14 (referred to herein as “circumferential protrusions”). Each circumferential protrusion may be spaced apart from another circumferential protrusion on microcannula 14 by a certain distance, such as a distance between about 40 μm and about 60 μm. In some implementations, each circumferential protrusion may be about 50 μm. Each circumferential protrusion may be of a certain height between about 15 μm and 35 μm. In some implementations, circumferential protrusions have height of 25 μm. Circumferential protrusions may be formed near the distal end of microcannula 14. In some implementations, circumferential protrusions may be formed starting from a location on microcannula 14 that is between about about 500 μm away and 250 μm away from the terminal end 98 of microcannula 14, for example, starting from about 350 μm away from the terminal end 98 of microcannula 14. Microcannula 14 may be formed of various materials including, but not limited to, polymethyl methacrylate (PMMA), polyimide, various types of silicones, such as high durometer silicone, and the like. Microcannula 14 may include or be coupled to a fastening mechanism. An example of such a fastening mechanism is a luer lock, such as luer lock 102, shown in
In some implementations, exemplary device 10 may include multiple cannula and/or microcannula, such as outer cannula 210, inner cannula 230, as shown in
Inner cannula 230 includes one or more protrusions, such as protrusions 240a, 240b, collectively referred to herein as protrusions 240, as shown in
Handle 12 may have an ergonomic shape designed to be held comfortably in the hand, e.g., the palm of the dominate hand of a medical professional. Handle 12 may have a length between about 5 inches (12.7 cm) and about 10 inches (25.4 cm) Handle 12 may include a proximal end 34, distal end 20, and a channel or track 36 extending there between, as will be descried in further detail below. Proximal end 34 and distal end 20 have a generally circular cross-sectional shape. Alternatively, proximal end 34 and distal end 20 may have any other cross-sectional shape (e.g., oval, polygonal, irregular, etc.) without departing from the scope of this disclosure. In some arrangements, the cross-sectional shape of proximal end 34 and/or distal end 20 may vary along the length of handle 12 and/or be different from each other. Optionally, proximal end 34 may be tapered or narrowed in a proximal direction, as shown.
Handle 12 includes an actuator 38. Actuator 38 includes a button or slide 40 received within track 36 of handle 12. In some arrangements, slide 40 may be at least partially bent or folded, as shown in
In some implementations, microcannula 14 is housed within an outer tube, such as outer tube 254, as shown in
In some implementations, microcannula 14 is movably housed within an outer sheath, such as outer sheath 260, as shown in
The application of the threshold amount of force to an actuator coupled to the microcannula 14, causing at least a portion of the microcannula 14 to extend outside of the outer sheath 260, causes at least that portion of the microcannula 14 to penetrate the trabecular meshwork of a patient, such as trabecular meshwork 86 (shown in
Track 36 extends through a radially outer wall of handle 12 with respect to the central longitudinal axis of handle 12. Accordingly, slide 40 may extend radially outwardly of the center axis through track 36. As shown, track 36 may be notched such that pairs of inwardly protruding notches, extensions, or flanges 48 extend towards each other to narrow a width of track 36 at a plurality of axially spaced locations along the length of track 36. In other words, track 36 extends longitudinally along handle 12 and has a width, extending in a direction perpendicular the longitudinal length of track 36. The width of track 36 varies along the length of the track 36 such that each location of track 36 having a pair of flanges 48 has a smaller or more narrow width than a width of track 36 at a location devoid of one or more flanges 48. An axial spacing between adjacent pairs of flanges 48 may directly correlate to an amount of a single dose or quantity of a substance (e.g., a fluid or gas) for injection via microcannula 14, as will be described in further detail below. Additionally, it is understood that slide 40 may be replaced with any appropriate actuator, e.g., wheel, button, toggle, or the like, without departing from the scope of this disclosure.
Turning to
A piston assembly including a piston rod 58 extends proximally through a central lumen 60 of microcannula 14, through lumen 22 of connector 16, through lumen 56 of distal end 20 of handle 12, and towards actuator body 44 housed within a cavity 62 of handle 12. Piston rod 58 may be reciprocally disposed within central lumen 60. A proximal end of piston rod 58 is fixedly coupled to actuator body 44 such that distal advancement of actuator body 44 will result in likewise distal advancement of piston rod 58. As shown in
In order to deliver fluid or other substances from reservoir 28, a medical professional may advance slide 40 distally towards microcannula 14. Due to the connection between first end 42 and actuator body 44, and the connection between actuator body 44 and piston rod 58, distal advancement of slide 40 advances piston head 64 towards orifices 32 to deliver fluid or other substances within central lumen 60 through orifices 32. Any appropriate mechanism may be used to urge fluid or substances within reservoir 28 through the piston passage 66, through the one-way valve 70 within the piston passage 66, and into the cavity 60. For example, reservoir 28 may be compressed thereby pushing fluid or other substances into and through the piston passage 66. Alternatively, fluid or other substances may be drawn through piston passage 66 via capillary action, via a micro pump (e.g., a MEMS pump) or any other suitable pump (not shown).
In some implementations, as shown in
In some implementations, handle 12 may include a visco bag and a button communicatively coupled to the visco bag with the visco bag in communication with an orifice 32 on the distal end 30. Depression of the button compresses visco bag and causes visco fluid to eject through the orifice 32 on the distal end 30. In some implementations, as shown in
As shown in
As noted above, axial spacing between adjacent pairs of flanges 48 of track 36 correlates to an amount of a single dose or quantity of fluid or other substance for injection via microcannula 14. For example, before advancement of slide 40, second end 46 of slide 40 is positioned between two adjacent first pairs of flanges 48, thus preventing inadvertent advancement (or retraction) of slide 40 and injection of fluid or other substances through orifices 32. To advance slide 40 and inject fluid or other substances via orifices 32, a medical professional must first overcome the resistance provided by the two adjacent first pairs of flanges 48 against the second end 46 of slide 40, and then continue advancing slide 40 to push or urge fluid or other substances in central lumen 60 distal of piston head 64 through orifices 32. That is, as slide 40 is urged distally forward, the angled or slanted surface of second end 46 will slide or move along surfaces of flanges 48 until second end 46 deflects radially inwardly towards the central axis of handle 12 and is positioned underneath flanges 48, at which point slide 40 can continue advancement distally.
As slide 40 continues distal advancement, second end 46 may be received between two adjacent second pairs of flanges 48 and retained therein, thus preventing further inadvertent advancement. For example, second end 46 may deflect radially outwardly away from the central axis of handle 12 (returning towards an undeflected orientation). It is understood, second end 46 may be biased radially outwardly toward the undeflected orientation. The two second adjacent pairs of flanges 48 may be adjacent (e.g., next to) the two adjacent first pairs of flanges 48. In other words, as slide 40 is advanced distally, interaction between second end 46 and each two adjacent pairs of flanges 48 will cause an increase of resistance exerted to the medical professional, thereby resulting in a tactile indication that a specified dose or amount of fluid or substance has been delivered through orifices 32.
In some implementations, as shown in the exploded view of
In some implementations, microcannula 14 includes a nitinol (NiTi) tube at the distal end of microcannula 14. The NiTi tube may be configured to the The NiTi tube at the distal end is configured to one bend in a certain direction after the NiTi tube travels a certain distance. In some implementations, handle 12 includes a control mechanism coupled to the NiTi tube and the control mechanism is configured to rotate NiTi tube 180 degrees in response to receiving an input or a user interacting with the control mechanism.
Turning now to
After injection of a pre-defined dose or amount of fluid or other substance through orifices 32 (
Optionally, after the injection of one or more pre-defined doses of fluid or other substance at a certain location within Schlemm's canal 80 (e.g., without relocating (other than rotating) distal end 30 of microcannula 14), distal end 30 may be retracted and repositioned within the eye. In some arrangements, such repositioning may occur via withdrawal of microcannula 14 from incision 88 (e.g., a first incision 88), and reinsertion through an additional incision 88, spaced from the first incision 88. In some implementations, fluid may be delivered into the Schlemm's canal 80 and trabecular meshwork 86 simultaneously, causing the Schlemm's canal 80 to open and deliver the fluid into the various layers of the trabecular meshwork 86. Alternatively, such repositioning may include retraction of distal end 30 from Schlemm's canal 80 and/or trabecular meshwork 86 and then relocation into a new portion of Schlemm's canal 80 without removal of microcannula 14 from the first incision 88. In either case, distal end 30 of microcannula 14 may be positioned approximately 30-90° away from the original insertion site.
The substance located within reservoir 28, and injected via orifices 32 may be any appropriate substance. For example, the substance may comprise viscoelastic fluid such as, e.g., sodium hyaluronate and chondroitin sulfate. Viscoelastic fluid is a highly pliable, gel-like material which helps provide enough space for adequate drainage and eye pressure relief by expanding tissue structures away from one another, to re-open or expand a flow path of aqueous humor 82. Viscoelastic fluid also may clear an obstructed view by expanding bleeding structures away from one another to improve visualization.
In another arrangement, reservoir 28 may be filled with stem cells, medicaments, a gas (e.g., SF6 or C3F8), and/or dyes (e.g., trypan blue dye). Injected dye, for example, will flow through the trabecular meshwork 86, enhancing visualization of aqueous humor 82 fluid flow to determine which areas, if any, of the trabecular meshwork 86 remain blocked, collapsed, or otherwise impede flow of aqueous humor 82. Injected stem cells, on the other hand, may initiate growth of healthy tissues within the eye (e.g., to develop healthy trabecular meshwork 86 to enhance drainage of aqueous humor 82 there through).
In some arrangements, a first substance is injected into one or more locations of the eye, the reservoir 28 is refilled with a second substance different than the first substance, and then the second substance is injected into one or more locations of the eye. Additionally, this process may be repeated as necessary to deliver each selected substance. For example, as noted above one or both of connector 16 and distal end 20 may include a fluid luer port (not shown), through which reservoir 28 may be selectively refilled. Accordingly, a plurality of substances, e.g., viscoelastic, medicament, stem cells, and dye, may be injected into the eye of a patient to achieve a desired result (e.g., visualize the flow path of aqueous humor 82, expand Schlemm's canal 80, promote tissue regrowth, or to otherwise medicinally treat diseased tissue). Accordingly, during a procedure, a single (e.g., only one) incision 88 may be needed to deliver a variety of substances as deemed necessary and/or beneficial by the medical professional, thus reducing trauma, recovery time, medical professional time, and associated fees, etc.
It is to be understood that while the foregoing description describes devices and methods for injection of a fluid or other substance through orifices 32, the disclosure is not so limited. Indeed, device 10 described herein may be arranged for precision-controlled aspiration of fluid or other substances away from the eye. For example, rather than distal advancement of slide 40 to incrementally inject a pre-defined “dose” or quantity of a substance or fluid radially outwardly of microcannula 14 via orifices 32, proximal retraction of slide 40 may incrementally draw (e.g., suction, pull, etc.) fluid or other substances (e.g., tissue, blood, aqueous humor 82, etc.) out of Schlemm's canal 80 for removal from the eye. In other words, device 10 may be actuated in a reverse manner from that described above to achieve a removal of fluid or other substances from the eye. In arrangements in which device 10 is positioned for removal of fluid or other substances from the eye, one or more components of device 10 may be reversed (e.g., one-way valve 70 may be oriented to permit proximal flow of fluid or other substance while preventing distal flow of fluid or other substance along piston passage 66, etc.). In some embodiments, microcannula 14 may be operably coupled to a suitable vacuum source for the generation of suction.
Device 10 may be comprised of any appropriate materials. For example, microcannula 14 may include one or more of metals (e.g., stainless steel, titanium, nitinol, etc.) or a rigid (e.g., sufficiently rigid to push through trabecular meshwork 86 and Schlemm's canal 80 without bending or otherwise deforming) polymer (e.g., PEEK, Polyimide, etc.). Exemplary materials also may include polymers transparent to optical coherence tomography (OCT) (e.g., glycol modified polyethylene terephthalate, polyvinal chloride, polymethyl methacrylate, and/or polyphenylsulfone, etc.) such that imaging via OCT can be done simultaneously with positioning of microcannula 14 and/or injection of a substance via orifices 32 while minimally disrupting the images obtained via OCT.
Additionally, any one or more portions of microcannula 14, e.g., distal end 30, may be radiopaque to enhance visualization by a medical professional during a procedure. Likewise, handle 12 may include any one or more metals or polymers, as appropriate. Additionally or alternatively, distal end 30 may include a light-emitting diode (LED) (not shown). When the LED is lit, the medical professional may be able to see the light through the sclera of the eye, giving the user an indication of the position of microcannula 14 in the eye. In some arrangements, one or more radiopaque indicia or other markings may be located at distal end 30 of microcannula 14 to facilitate visualization of the depth of microcannula 14 into the eye of the patient. Additionally, microcannula 14 may include a cutting device (e.g., knife, blade, point tip, etc.) (not shown) adjacent distal end 30. In use, such a cutting device may enable a medical professional to cut tissue (e.g., trabecular meshwork 86 and/or Schlemm's canal 80) prior to or following injection of a substance via orifices 32. For example, microcannula 14 including the cutting device may be moved side-to-side to cut the tissue lifted due to injection of the substance via orifices 32.
While principles of the present disclosure are described herein with reference to illustrative embodiments for particular applications, it should be understood that the disclosure is not limited thereto. Those having ordinary skill in the art and access to the teachings provided herein will recognize additional modifications, applications, embodiments, and substitution of equivalents all fall within the scope of the embodiments described herein. Accordingly, the invention is not to be considered as limited by the foregoing description.
A reference to an element in the singular is not intended to mean one and only one unless specifically so stated, but rather one or more. For example, “a” module may refer to one or more modules. An element proceeded by “a,” “an,” “the,” or “said” does not, without further constraints, preclude the existence of additional same elements.
Headings and subheadings, if any, are used for convenience only and do not limit the invention. The word exemplary is used to mean serving as an example or illustration. To the extent that the term include, have, or the like is used, such term is intended to be inclusive in a manner similar to the term comprise as comprise is interpreted when employed as a transitional word in a claim. Relational terms such as first and second and the like may be used to distinguish one entity or action from another without necessarily requiring or implying any actual such relationship or order between such entities or actions.
Phrases such as an aspect, the aspect, another aspect, some aspects, one or more aspects, an implementation, the implementation, another implementation, some implementations, one or more implementations, an embodiment, the embodiment, another embodiment, some embodiments, one or more embodiments, a configuration, the configuration, another configuration, some configurations, one or more configurations, the subject technology, the disclosure, the present disclosure, other variations thereof and alike are for convenience and do not imply that a disclosure relating to such phrase(s) is essential to the subject technology or that such disclosure applies to all configurations of the subject technology. A disclosure relating to such phrase(s) may apply to all configurations, or one or more configurations. A disclosure relating to such phrase(s) may provide one or more examples. A phrase such as an aspect or some aspects may refer to one or more aspects and vice versa, and this applies similarly to other foregoing phrases.
A phrase “at least one of” preceding a series of items, with the terms “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list. The phrase “at least one of” does not require selection of at least one item; rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items. By way of example, each of the phrases “at least one of A, B, and C” or “at least one of A, B, or C” refers to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.
It is understood that the specific order or hierarchy of steps, operations, or processes disclosed is an illustration of exemplary approaches. Unless explicitly stated otherwise, it is understood that the specific order or hierarchy of steps, operations, or processes may be performed in different order. Some of the steps, operations, or processes may be performed simultaneously. The accompanying method claims, if any, present elements of the various steps, operations or processes in a sample order, and are not meant to be limited to the specific order or hierarchy presented. These may be performed in serial, linearly, in parallel or in different order. It should be understood that the described instructions, operations, and systems can generally be integrated together in a single software/hardware product or packaged into multiple software/hardware products.
In one aspect, a term coupled or the like may refer to being directly coupled. In another aspect, a term coupled or the like may refer to being indirectly coupled.
Terms such as top, bottom, front, rear, side, horizontal, vertical, and the like refer to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference. Thus, such a term may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.
The disclosure is provided to enable any person skilled in the art to practice the various aspects described herein. In some instances, well-known structures and components are shown in block diagram form in order to avoid obscuring the concepts of the subject technology. The disclosure provides various examples of the subject technology, and the subject technology is not limited to these examples. Various modifications to these aspects will be readily apparent to those skilled in the art, and the principles described herein may be applied to other aspects.
All structural and functional equivalents to the elements of the various aspects described throughout the disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. § 112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for”.
The title, background, brief description of the drawings, abstract, and drawings are hereby incorporated into the disclosure and are provided as illustrative examples of the disclosure, not as restrictive descriptions. It is submitted with the understanding that they will not be used to limit the scope or meaning of the claims. In addition, in the detailed description, it can be seen that the description provides illustrative examples and the various features are grouped together in various implementations for the purpose of streamlining the disclosure. The method of disclosure is not to be interpreted as reflecting an intention that the claimed subject matter requires more features than are expressly recited in each claim. Rather, as the claims reflect, inventive subject matter lies in less than all features of a single disclosed configuration or operation. The claims are hereby incorporated into the detailed description, with each claim standing on its own as a separately claimed subject matter.
The claims are not intended to be limited to the aspects described herein, but are to be accorded the full scope consistent with the language of the claims and to encompass all legal equivalents. Notwithstanding, none of the claims are intended to embrace subject matter that fails to satisfy the requirements of the applicable patent law, nor should they be interpreted in such a way.
This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/436,099, titled “OCCULAR TREATMENT DEVICES AND RELATED METHODS OF USE,” and filed on Dec. 19, 2016, the entirety of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3439675 | Cohen | Apr 1969 | A |
4373526 | Kling | Feb 1983 | A |
4401124 | Guess et al. | Aug 1983 | A |
4699612 | Hamacher | Oct 1987 | A |
4764165 | Reimels et al. | Aug 1988 | A |
4795446 | Fecht | Jan 1989 | A |
4904238 | Williams | Feb 1990 | A |
4940468 | Petillo | Jul 1990 | A |
4955883 | Nevyas | Sep 1990 | A |
5407441 | Greenbaum | Apr 1995 | A |
5449351 | Zohmann | Sep 1995 | A |
5487725 | Peyman | Jan 1996 | A |
5681291 | Galli | Oct 1997 | A |
5755700 | Kritzinger et al. | May 1998 | A |
5848996 | Eldor | Dec 1998 | A |
6102896 | Roser | Aug 2000 | A |
6126629 | Perkins | Oct 2000 | A |
6135984 | Dishler | Oct 2000 | A |
6162202 | Sicurelli et al. | Dec 2000 | A |
6375648 | Edelman et al. | Apr 2002 | B1 |
6413245 | Yaacobi et al. | Jul 2002 | B1 |
6494868 | Amar | Dec 2002 | B2 |
6613026 | Palasis et al. | Sep 2003 | B1 |
6802829 | Buono | Oct 2004 | B2 |
6969373 | Schwartz et al. | Nov 2005 | B2 |
7141048 | Charles | Nov 2006 | B1 |
7361158 | Mooney, Jr. | Apr 2008 | B1 |
7931622 | Beling et al. | Apr 2011 | B2 |
7998108 | Nazzaro et al. | Aug 2011 | B2 |
8529541 | Klein | Sep 2013 | B2 |
8608632 | Brigatti et al. | Dec 2013 | B1 |
8622977 | Persat | Jan 2014 | B2 |
9050167 | Akahoshi | Jun 2015 | B2 |
9220850 | Kawamoto et al. | Dec 2015 | B2 |
9233195 | Akahoshi | Jan 2016 | B2 |
9439807 | Koplin | Sep 2016 | B2 |
9440050 | Katase et al. | Sep 2016 | B2 |
9457183 | Sallberg et al. | Oct 2016 | B2 |
9486583 | Lannan et al. | Nov 2016 | B2 |
9498377 | McCary et al. | Nov 2016 | B2 |
9592352 | Matsuzawa | Mar 2017 | B2 |
20020111608 | Baerveldt | Aug 2002 | A1 |
20040147883 | Tsai | Jul 2004 | A1 |
20050020990 | Akahoshi | Jan 2005 | A1 |
20050197633 | Schwartz | Sep 2005 | A1 |
20060047254 | Akahoshi | Mar 2006 | A1 |
20060100653 | Akahoshi | May 2006 | A1 |
20060223026 | Kuroiwa et al. | Oct 2006 | A1 |
20060259006 | McKay et al. | Nov 2006 | A1 |
20060259008 | Orilla | Nov 2006 | A1 |
20060276552 | Barbut | Dec 2006 | A1 |
20070118142 | Krueger et al. | May 2007 | A1 |
20070282254 | Chow | Dec 2007 | A1 |
20080082078 | Berlin | Apr 2008 | A1 |
20080172012 | Hiniduma-Lokuge et al. | Jul 2008 | A1 |
20080249522 | Pappone et al. | Oct 2008 | A1 |
20090099478 | Cassells et al. | Apr 2009 | A1 |
20100121284 | Hexsel | May 2010 | A1 |
20100324530 | Hertzog | Dec 2010 | A1 |
20110034864 | Dacquay | Feb 2011 | A1 |
20110046600 | Crank | Feb 2011 | A1 |
20110092885 | Myoshi | Apr 2011 | A1 |
20130253438 | Badawi et al. | Sep 2013 | A1 |
20140081194 | Burns et al. | Mar 2014 | A1 |
20140100426 | Barbour | Apr 2014 | A1 |
20150051581 | Andino et al. | Feb 2015 | A1 |
20150209180 | Prausnitz | Jul 2015 | A1 |
20150223977 | Oberkircher et al. | Aug 2015 | A1 |
20150335487 | de Juan, Jr. | Nov 2015 | A1 |
20150342784 | Seiler et al. | Dec 2015 | A1 |
20160045707 | Conti | Feb 2016 | A1 |
20160106461 | Morris | Apr 2016 | A1 |
20160303333 | Momose | Oct 2016 | A1 |
20170007776 | Sahin | Jan 2017 | A1 |
Number | Date | Country |
---|---|---|
105919724 | Sep 2016 | CN |
29909787 | Sep 1999 | DE |
102005049791 | Apr 2007 | DE |
102009049153 | Apr 2011 | DE |
202011100654 | Oct 2011 | DE |
2986419 | Aug 2013 | FR |
3012041 | Apr 2015 | FR |
858913 | Jan 1961 | GB |
2202747 | Oct 1988 | GB |
WO-1990001349 | Feb 1990 | WO |
WO-1997014454 | Apr 1997 | WO |
WO-2002058607 | Aug 2002 | WO |
WO-2010026644 | Mar 2010 | WO |
WO-2011141940 | Nov 2011 | WO |
WO-2014061030 | Apr 2014 | WO |
WO-2016133334 | Aug 2016 | WO |
WO-2016192739 | Dec 2016 | WO |
WO-2017053572 | Mar 2017 | WO |
WO-2017168015 | Oct 2017 | WO |
Entry |
---|
International Search Report and Written Opinion for Application No. PCT/US17/67126, dated Apr. 24, 2018, 14 pages. |
Tran Canula® Technical Sheet, fabrinal Eye Care, 2018, retrieved from http://fabrinal.ch/pdf/63/technical-sheet-tran_canula_e_b08.2018.pdf. |
Number | Date | Country | |
---|---|---|---|
20180168863 A1 | Jun 2018 | US |
Number | Date | Country | |
---|---|---|---|
62436099 | Dec 2016 | US |